Latest Rosalind Advisors, Inc. Stock Portfolio
$248Million | No. of Holdings #32
Rosalind Advisors, Inc. Performance
2026 Q1-10.95%
YTD-10.95%
2025+14.98%
About Rosalind Advisors, Inc. and 13F Hedge Fund Stock Holdings
On 2026-05-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Rosalind Advisors, Inc. reported an equity portfolio of $248.9 Millions as of 31 Mar, 2026. <br><br> The top stock holdings of Rosalind Advisors, Inc. are DCTH, XERS, FENC. The fund has invested 12.3% of it's portfolio in DELCATH SYSTEMS, INC. and 7.5% of portfolio in XERIS BIOPHARMA HOLDINGS INC. <br><br> The fund managers got completely rid off REPLIMUNE GROUP INC (REPL), ASTRIA THERAPEUTICS INC (LIFE) and CYTOKINETICS INC (CYTK) stocks. They significantly reduced their stock positions in CG ONCOLOGY INC, VIRIDIAN THERAPEUTICS INC (VRDN) and PROFOUND MEDICAL CORP (PROF). Rosalind Advisors, Inc. opened new stock positions in VAXCYTE INC (PCVX), VOR BIOPHARMA INC (VOR) and CELLDEX THERAPEUTICS INC (CLDX). The fund showed a lot of confidence in some stocks as they added substantially to XERIS BIOPHARMA HOLDINGS INC (XERS), EYEPOINT PHARMACEUTICALS INC (EYPT) and X4 PHARMACEUTICALS INC (XFOR).
Rosalind Advisors, Inc. Equity Portfolio Value
Last Reported on: 14 May, 2026
$248Million
as of May 14, 2026Rosalind Advisors, Inc. Annual Return Estimates Vs S&P 500
Our best estimate is that Rosalind Advisors, Inc. made a return of -10.95% in the last quarter. In trailing 12 months, it's portfolio return was 19.79%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| vaxcyte inc | 16,851,900 |
| vor biopharma inc | 12,488,000 |
| celldex therapeutics inc | 10,467,600 |
| biocryst pharmaceuticals inc | 8,787,500 |
| atea pharmaceuticals inc | 6,304,580 |
| ovid therapeutics inc | 2,459,750 |
| definium therapeutics inc | 2,362,500 |
| lipocine inc | 1,770,710 |
New stocks bought by Rosalind Advisors, Inc.
Additions
| Ticker | % Inc. |
|---|---|
| xeris biopharma holdings inc | 53.04 |
| eyepoint pharmaceuticals inc | 50.25 |
| x4 pharmaceuticals inc | 23.36 |
| verastem inc | 19.57 |
| fennec pharmaceuticals inc | 11.28 |
| biofrontera inc | 2.03 |
| myomo inc | 0.2 |
Additions to existing portfolio by Rosalind Advisors, Inc.
Reductions
| Ticker | % Reduced |
|---|---|
| cg oncology inc | -66.67 |
| viridian therapeutics inc | -44.36 |
| onkure therapeutics inc | -39.25 |
| profound medical corp | -22.53 |
| polypid ltd | -14.16 |
| cybin inc | -7.59 |
| talphera inc | -6.3 |
| savara inc | -5.88 |
Rosalind Advisors, Inc. reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| replimune group inc | -13,710,000 |
| astria therapeutics inc | -13,601,600 |
| mind medicine mindmed inc | -10,042,500 |
| ocular therapeutix, inc | -4,856,000 |
| fractyl health inc | -848,608 |
| arrivent biopharma inc | -4,343,320 |
| cytokinetics inc | -12,393,200 |
| trevi therapeutics inc | -1,252,000 |
Rosalind Advisors, Inc. got rid off the above stocks
Sector Distribution
Rosalind Advisors, Inc. has about 83.3% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 83.3 |
| Others | 16.7 |
Market Cap. Distribution
Rosalind Advisors, Inc. has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- SMALL-CAP
- MICRO-CAP
- UNALLOCATED
- MID-CAP
- NANO-CAP
| Category | % |
|---|---|
| SMALL-CAP | 49.2 |
| MICRO-CAP | 22 |
| UNALLOCATED | 16.7 |
| MID-CAP | 8.9 |
| NANO-CAP | 3.2 |
Stocks belong to which Index?
About 59.4% of the stocks held by Rosalind Advisors, Inc. either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 59.4 |
| Others | 40.6 |
Rosalind Advisors, Inc. Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Rosalind Advisors, Inc.
Rosalind Advisors, Inc. has 32 stocks in it's portfolio. About 65.9% of the portfolio is in top 10 stocks. XERS proved to be the most loss making stock for the portfolio. was the most profitable stock for Rosalind Advisors, Inc. last quarter.
$244.08MTotal Value
40.00Positions
14 May, 2026Last Reported
| Expand | Holdingsorted ascending | % Portfolio | Shares Held | $ Value | % Change |
|---|---|---|---|---|---|
 Talphera Inc Talphera IncACRX Rosalind Advisors, Inc.'s holding in Talphera Inc over time | 1.01% | 3,353,920 | $2.51M 1.01% | 6.3%decreased 6.3 percentreduced | |
 Annexon Inc Annexon IncANNX Rosalind Advisors, Inc.'s holding in Annexon Inc over time | 0.44% | 200,000 | $1.11M 0.44% | Newnew position | |
 Aquestive Therapeutics Inc Rosalind Advisors, Inc.'s holding in Aquestive Therapeutics Inc over time | 0.42% | 250,000 | $1.04M 0.42% | Newnew position | |
 Atea Pharmaceuticals Inc Rosalind Advisors, Inc.'s holding in Atea Pharmaceuticals Inc over time | 2.53% | 1,171,860 | $6.30M 2.53% | Newnew position | |
 Avalo Therapeutics Inc Rosalind Advisors, Inc.'s holding in Avalo Therapeutics Inc over time | 0.45% | 75,000 | $1.12M 0.45% | Newnew position | |
 Biocryst Pharmaceuticals Inc Rosalind Advisors, Inc.'s holding in Biocryst Pharmaceuticals Inc over time | 3.53% | 923,057 | $8.79M 3.53% | Newnew position | |
 Biofrontera Inc Biofrontera IncBFRI Rosalind Advisors, Inc.'s holding in Biofrontera Inc over time | 0.38% | 1,163,960 | $941.6K 0.38% | 2.03%increased 2.03 percentadded | |
 Celldex Therapeutics Inc Rosalind Advisors, Inc.'s holding in Celldex Therapeutics Inc over time | 4.21% | 330,000 | $10.47M 4.21% | Newnew position | |
 CYBN Cybin IncCybin IncCYBN | 2.95% | 1,531,810 | $7.35M 2.95% | 7.59%decreased 7.59 percentreduced | |
 Cytokinetics Inc Cytokinetics IncCYTK Rosalind Advisors, Inc.'s holding in Cytokinetics Inc over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Delcath Systems, Inc. Rosalind Advisors, Inc.'s holding in Delcath Systems, Inc. over time | 12.31% | 3,300,390 | $30.63M 12.31% | 0%unchanged 0 percentunchanged | |
 Eyepoint Pharmaceuticals Inc Rosalind Advisors, Inc.'s holding in Eyepoint Pharmaceuticals Inc over time | 5.37% | 1,036,740 | $13.36M 5.37% | 50.25%increased 50.25 percentadded | |
 Fennec Pharmaceuticals Inc Rosalind Advisors, Inc.'s holding in Fennec Pharmaceuticals Inc over time | 7.19% | 2,908,200 | $17.89M 7.19% | 11.28%increased 11.28 percentadded | |
 Kura Oncology Inc Rosalind Advisors, Inc.'s holding in Kura Oncology Inc over time | 0.33% | 100,000 | $813.0K 0.33% | 0%unchanged 0 percentunchanged | |
 Astria Therapeutics Inc Rosalind Advisors, Inc.'s holding in Astria Therapeutics Inc over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Lipocine Inc Lipocine IncLPCN Rosalind Advisors, Inc.'s holding in Lipocine Inc over time | 0.71% | 221,616 | $1.77M 0.71% | Newnew position | |
 MDWD Mediwound LtdMediwound LtdMDWD | 4.85% | 749,054 | $12.07M 4.85% | 0%unchanged 0 percentunchanged | |
 Mind Medicine Mindmed Inc Rosalind Advisors, Inc.'s holding in Mind Medicine Mindmed Inc over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
| 1.04% | 3,847,270 | $2.60M 1.04% | 0.2%increased 0.2 percentadded | ||
 Inspiremd Inc Inspiremd IncNSPR Rosalind Advisors, Inc.'s holding in Inspiremd Inc over time | 2.56% | 3,905,740 | $6.37M 2.56% | 0%unchanged 0 percentunchanged | |
